Actavis Reaches Tentative Deal To Exit Testosterone MDL
Actavis Inc. is on its way to settling claims it failed to warn men about risks associated with its drug Androderm as part of multidistrict litigation over testosterone replacement therapy products,...To view the full article, register now.
Already a subscriber? Click here to view full article